Table 2.
Morbidities of thalassemia intermedia.
| Studies, n (%) | ORIENT Study, No Iron Chelation or Fetal Hemoglobin Induction; n = 52 (β-TI) [42] | KM Musallamb, 2011, n = 168 (β-TI) [33] | OPTIMAL CARE Study, 2010, n = 584 TI [16] |
|---|---|---|---|
| Age (years), mean (SD) | 24.1 ± 1.6 (range 2–56) | 35.2 (12.6) | 25.44 ± 13.86 (2–76) |
| Male, n (%) | 25 (48.1) | 73 (42.9) | 291:293 |
| Splenectomized, n (%) | 30 (57.7) | 121 (72.0) | 325 (55.7) |
| Transfusion history, n (%) | No regularly blood transfusion | ||
| None | 44 (26.2) | 139 (23.8) | |
| Occasional | 80 (47.6) | 143 (24.5) | |
| Regular | 44 (26.2) | 302 (51.7) | |
| Age (years), mean (SD) | 24.1 ± 1.6 (range 2–56) | 35.2 (12.6) | 25.44 ± 13.86 (2–76) |
| Male, n (%) | 25 (48.1) | 73 (42.9) | 291:293 |
| Splenectomized, n (%) | 30 (57.7) | 121 (72.0) | 325 (55.7) |
| Morbidity, n (%) | 36 (69.2) | ||
| Osteoporosis | 25 (48.1) | 77 (45.8) | 134 (22.9) |
| Extramedullary hematopoiesis | 10 (19.2) | 43 (25.6) | 124 (21.2) |
| Liver disease | 9 (17.3) (No B, C carrier) | 54 (32.1) | 57 (9.8) |
| Hypogonadism | 4 (7.7) | 28 (16.7) | 101 (17.3) |
| DM | 4 (7.7) | 6 (3.6) | 10 (1.7) |
| Thrombosis | 3(5.8) | 44 (26.2) | 82 (14) |
| Pulmonary hypertension | 1 (1.9) | 56 (33.3) | 64 (11) |
| Hypoparathyroidism | 1 (1.9) | ||
| Leg ulcers | 41 (24.4) | 46 (7.9) | |
| Hypothyroidism | 5 (9.6) | 30 (17.9) | 33 (5.7) |
| Heart failure | 9 (5.4) | 25 (4.3) | |
| cholelithiasis | 100 (17.1) |